Johnson & Johnson’s Innovative Medicine division enters the fourth quarter with multiple high-growth franchises offsetting biosimilar and Medicare Part D pressures. Immunology lead Stelara faces third-party competition in dermatology, yet oncology agent Darzalex expanded U.S. market share by over 2 percentage points sequentially, driving a mid-teens growth rate across the franchise. Blood cancer treatment Imbruvica contributed double-digit revenue growth outside the U.S., while newly launched Vabysmo achieved over 150,000 cumulative patient treatments globally by year-end. Management forecasts segment revenues to increase low-single digits year-over-year, with operating margin improvements fueled by ongoing manufacturing efficiencies and disciplined reinvestment in late-stage pipeline programs.

In the randomized, placebo-controlled JASMINE trial involving 228 patients with moderate to severe systemic lupus erythematosus, FcRn blocker nipocalimab met its primary endpoint of SLE Responder Index-4 response at Week 24, delivering a 22-point absolute improvement versus placebo. Key secondary measures—including reduction in corticosteroid use and decrease in anti-double-stranded DNA antibody titers—also achieved statistical significance. Safety data showed comparable rates of adverse events between treatment and control arms, with no new safety signals. J&J plans to initiate global Phase III studies in the first half of 2026, targeting regulatory submissions by late 2027.

Johnson & Johnson MedTech has filed a De Novo request for its OTTAVA™ soft-tissue robotic surgical system, leveraging data from its IDE trial completed at Memorial Hermann-Texas Medical Center. Investigators reported successful completion of upper-abdomen procedures—gastric bypass, sleeve gastrectomy and hiatal hernia repair—with precision metrics exceeding predefined thresholds for instrument articulation and suturing accuracy. The unified robotic architecture integrates Ethicon-powered instrumentation and is designed to support multi-quadrant access. A second IDE study in inguinal hernia repair was approved in late 2025. JNJ anticipates a De Novo decision by mid-2026, paving the way for U.S. commercialization and integration into its Polyphonic™ digital ecosystem.